Harvard Bioscience(US:HBIO) Globenewswire·2026-03-12 11:30Core Insights - Harvard Bioscience, Inc. reported financial results for Q4 and the full year 2025, highlighting a transition towards becoming a leader in translational science and a focus on New Approach Methodologies (NAMs) [2][9] Financial Performance - Q4 2025 revenues were $23.7 million, a decrease from $24.6 million in Q4 2024, while gross margin improved to 59.7% from 57.1% year-over-year due to cost containment and a favorable product mix [3] - The net loss for Q4 2025 was ($2.8) million compared to a net income of $18 thousand in Q4 2024, with adjusted EBITDA increasing to $3.8 million from $3.0 million [4] - For the full year 2025, revenues totaled $86.6 million, down from $94.1 million in 2024, attributed to a challenging global market and reduced spending by customers [5] - The gross margin for the year was 57.7%, slightly down from 58.2% in 2024, impacted by fixed manufacturing overhead costs [5] - The net loss for 2025 was ($56.7) million, significantly higher than the ($12.4) million loss in 2024, primarily due to a goodwill impairment of $48.0 million [6] Operational Developments - The company has streamlined its operating model and strengthened its balance sheet throughout 2025, positioning itself for future growth [2] - Mark Frost has been appointed as the permanent CFO, expressing optimism about the company's future and engagement with stakeholders [2] Future Outlook - Guidance for 2026 anticipates revenue growth driven by new product innovations in translational science, supported by a stabilized NIH funding environment and reduced tariff disruptions [11] - The company expects revenue growth between 2% and 4%, with adjusted gross margins between 58% and 60% and adjusted EBITDA growth between 6% and 10% [16]